Reduced-Dose Edoxaban in Patients Aged ≥ 80 Years: A Single-Center Real-World Analysis
Reduced-dose edoxaban demonstrates a favorable safety-efficacy profile in advanced-age patients, necessitating comprehensive bleeding-ischemic risk assessment to optimize individualized anticoagulation regimens.
Authors
- Jiali Du (ORCID: https://orcid.org/0000-0003-0795-8409)
- Ruiqi Zhang (ORCID: https://orcid.org/0000-0001-7137-7807)
- Meilin Liu (ORCID: https://orcid.org/0000-0001-7580-8117)
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- Drugs & Aging
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1007/s40266-025-01247-9
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Peking University First Hospital
- Peking University